Skip to main navigation Skip to search Skip to main content

Pneumococcal conjugate vaccines

  • Carla C.A.M. Peeters*
  • , Anne Marie Tenbergen-Meekes
  • , Bart Haagmans
  • , Dolf Evenberg
  • , Jan T. Poolman
  • , Ben J.M. Zegers
  • , Ger T. Rijkers
  • *Corresponding author for this work
  • Utrecht University
  • National Institute of Public Health and the Environment
  • Wilhelmina Kinderziekenhuis

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein. In general, polysaccharide conjugates induced higher anti-PS4 IgG antibody titers than oligosaccharide conjugates. Conjugates with the highest amount of incorporated protein were the most immunogenic. The response to conjugated PS4 does show characteristics of a T cell-dependent antibody response, in terms of both isotype distribution and induction of immunological memory. Repeated immunization with high doses of PS4TT conjugate resulted in a virtually negative anti-PS4 IgG response, suggestive of the induction of high dose tolerance.

Original languageEnglish
Pages (from-to)267-274
Number of pages8
JournalImmunology Letters
Volume30
Issue number2
DOIs
Publication statusPublished - Oct 1991
Externally publishedYes

Bibliographical note

Copyright © 1991 Published by Elsevier B.V

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pneumococcal conjugate vaccines'. Together they form a unique fingerprint.

Cite this